Applied Molecular Transport Inc. logo

AMTI - Applied Molecular Transport Inc. Share Price

$22.37 0.3  1.2%

Last Trade - 10/07/20

Market Cap £568.4m
Enterprise Value £639.5m
Revenue £n/a
Position in Universe 2546th / 6345
Bullish
Bearish
Unlock AMTI Revenue
Momentum
Relative Strength (%)
1m +8.59%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -30.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Applied Molecular Transport Inc. revenues was not reported. Net loss increased from $5M to $15.3M. Higher net loss reflects Research and development increase from $4.3M to $12.6M (expense), General and administrative increase from $602K to $2.3M (expense), Stock-based Compensation in R&D increase from $36K to $328K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

AMTI Revenue Unlock AMTI Revenue

Net Income

AMTI Net Income Unlock AMTI Revenue

Normalised EPS

AMTI Normalised EPS Unlock AMTI Revenue

PE Ratio Range

AMTI PE Ratio Range Unlock AMTI Revenue

Dividend Yield Range

AMTI Dividend Yield Range Unlock AMTI Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AMTI EPS Forecasts Unlock AMTI Revenue
Profile Summary

Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company. The Company is leveraging its technology platform to design and develop a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The Company is building a portfolio of oral product candidates based on its technology platform including its product candidate, AMT-101, an oral GI-selective rhIL-10 that has completed a Phase 1b clinical trial in patients with ulcerative colitis (UC). The Company’s other product candidate, AMT-126, is a GI-selective oral fusion of rhIL-22. The Company’s technology platform enables it to design and develop various oral biologic therapeutic modalities, such as peptides, proteins, full-length antibodies, antibody fragments, and ribonucleic acid (RNA) therapeutics, with development-stage drugs.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
No. of Shareholders: n/a
No. of Employees: 49
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 32,400,624
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AMTI Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AMTI
Upcoming Events for AMTI
Frequently Asked Questions for Applied Molecular Transport Inc.
What is the Applied Molecular Transport Inc. share price?

As of 10/07/20, shares in Applied Molecular Transport Inc. are trading at $22.37, giving the company a market capitalisation of £568.4m. This share price information is delayed by 15 minutes.

How has the Applied Molecular Transport Inc. share price performed this year?

Shares in Applied Molecular Transport Inc. are currently trading at $22.37 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Applied Molecular Transport Inc. price has moved by % over the past year.

What are the analyst and broker recommendations for Applied Molecular Transport Inc.?

There are no analysts currently covering Applied Molecular Transport Inc..

When will Applied Molecular Transport Inc. next release its financial results?

Applied Molecular Transport Inc. is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Applied Molecular Transport Inc. dividend yield?

Applied Molecular Transport Inc. does not currently pay a dividend.

Does Applied Molecular Transport Inc. pay a dividend?

Applied Molecular Transport Inc. does not currently pay a dividend.

When does Applied Molecular Transport Inc. next pay dividends?

Applied Molecular Transport Inc. does not currently pay a dividend.

How do I buy Applied Molecular Transport Inc. shares?

To buy shares in Applied Molecular Transport Inc. you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Applied Molecular Transport Inc.?

Shares in Applied Molecular Transport Inc. are currently trading at $22.37, giving the company a market capitalisation of £568.4m.

Where are Applied Molecular Transport Inc. shares listed? Where are Applied Molecular Transport Inc. shares listed?

Here are the trading details for Applied Molecular Transport Inc.:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: AMTI
What kind of share is Applied Molecular Transport Inc.?

Based on an overall assessment of its quality, value and momentum, Applied Molecular Transport Inc. is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Applied Molecular Transport Inc. share price forecast 2020?

We were not able to load any forecast data for Applied Molecular Transport Inc..

How can I tell whether the Applied Molecular Transport Inc. share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Applied Molecular Transport Inc.. Over the past six months, the relative strength of its shares against the market has been %. At the current price of $22.37, shares in Applied Molecular Transport Inc. are trading at -12.04% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Applied Molecular Transport Inc. PE Ratio?

We were not able to find PE ratio data for Applied Molecular Transport Inc..

Who are the key directors of Applied Molecular Transport Inc.?

Applied Molecular Transport Inc.'s management team is headed by:

Helen Kim - CHM
David Lamond - IND
Aaron VanDevender - IND
Graham Cooper - IND
Tahir Mahmood - CEO
Randall Mrsny - CFD
Shawn Cross - CFO
Elizabeth Bhatt - OTH
Bittoo Kanwar - OTH
Derek Maclean - VPR
Chuck Olson - SVP
Andy Whitney - VPR
Who are the major shareholders of Applied Molecular Transport Inc.?

Here are the top five shareholders of Applied Molecular Transport Inc. based on the size of their shareholding:

EPIQ Capital Group, LLC Investment Advisor
Percentage owned: 23.62% (8.04m shares)
Founders Fund Venture Capital
Percentage owned: 13.03% (4.44m shares)
Mrsny (Randall) Individual Investor
Percentage owned: 10.57% (3.60m shares)
Mahmood (Tahir) Individual Investor
Percentage owned: 10.57% (3.60m shares)
Sheatree Direct, L.L.C. Corporation
Percentage owned: 3.48% (1.18m shares)
Similar to AMTI
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.